Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.

biopharmadive.com

Akero says MASH drug reverses liver damage in study, doubling shares

The performance of Akero's drug, called efruxifermin, in the severe MASH study outperformed investors' expectations.

Ad Fontes Media

All Sides

Media Bias/Fact Check

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

United States

Akero drug reverses liver scarring in study of severe MASH patients

Akero Therapeutics reported that at 96 weeks, 39% of patients who received the 50 mg dose of efruxifermin achieved improvement in fibrosis, or liver scarring, caused by the fatty liver disease MASH. This study previously failed to achieve statistically significant improvement at 36 weeks, but Akero executives say the latest results show that longer dosing matters. The post Akero Smashes Expectations in MASH, Showing Its Drug Reverses Fibrosis in…

MedCity News

Akero Smashes Expectations in MASH, Showing Its Drug Reverses Fibrosis in Fatty Livers

Phase 2b trial results published in NEJM Evidence show DURECT's larsucosterol achieved 57% mortality reduction in US patients with severe alcohol-associated hepatitis. Phase 3 planned for 2025.

stocktitan.net

Revolutionary Liver Disease Drug Cuts Death Risk by More Than Half in US Patients

This article was written by 
Follow 
Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis…

The Business Times

Akero: Reversal Of Cirrhosis With EFX Is A "First" In F4 MASH Patients (NASDAQ:AKRO)

Plus, news about Vigonvita Life Sciences and Lutris Pharma:
For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering that was announced the same ...

Endpoints News

Akero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drug

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition of efruxifermin.

ajmc.com

Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes

Preliminary topline week 96 results showed statistically significant reversal of MASH compensated cirrhosis with efruxifermin in complete and ITT analyses.

hcplive.com

Efruxifermin Reverses MASH Compensated Cirrhosis in Phase 2b SYMMETRY Study

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated cirrhosis (F4)The post Akero’s cirrhosis treatment shows promise in Phase IIb study appeared first on Clinical Trials Arena.

Clinical Trials Arena

Akero's cirrhosis treatment shows promise in Phase IIb study

Akero Therapeutics nearly doubles stock price on positive clinical studies, especially for its liver protecting drug candidate.

Akero says MASH drug reverses liver damage in study, doubling shares

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics